Zydus Lifesciences beats estimates, sees high-teens growth in FY27
Zydus Lifesciences beat market forecasts with revenue for the last quarter of 2025-26 up 16% year-on-year, with net profit adjusted for exceptional items rising 15% year-on-year.
The Ahmedabad-based drugmaker is forecasting high levels of growth in 2026-27, the company’s top executive told investors in a post-earnings call on Tuesday.
Revenue from operations increased in Q22020 ₹7,587 crore while adjusted net profit is ₹1,593 crore. EBITDA increased by 20 percent ₹2,554.4 crore, the margin increased by 110 basis points to 33.7%. EBITDA is an abbreviation for earnings before interest, taxes, depreciation and amortization.
A. Bloomberg Based on a survey of analysts, March quarter revenue is estimated as follows: ₹7,024.4 crore and net profit ₹946.4 crore.
Revenue from operations for FY26 was as follows: ₹27,148.4 crore, up 17% YoY and adjusted net profit up 15% ₹5,456.4 crore. EBITDA (previous value) ₹84,751 crore with a margin of 31.2%, up 20% year-on-year.
High growth projection
“Looking forward, as we look at consolidated revenue, we will continue to see high junior growth for FY27. Despite the high base for North America in FY26, we still expect to see single-digit growth in the North American business, aided by the portfolio,” Managing Director Sharvil Patel said on the post-earnings investor call.
“We have consistently shown better than market growth in India and we think we will outperform the market by 200-400 basis points compared to the current Indian pharmaceutical market (IPM),” Patel said, adding that the drugmaker expects the growth momentum to continue in its international market business, which grew 45% on an annual basis in the 4th quarter.
“As we move into specialization, we encourage growth through multiple tools,” Patel said. The company has many products in production.
This includes products filed through 505(b)(2) in the US, which allows new drug applications to be approved based in part on existing data rather than conducting studies from scratch. The rare disease portfolio also continues to attract attention. The company has licensed two major molecules in biosimilars and is strengthening its capabilities through its newly acquired manufacturing facilities from Agenus Inc. in 2025.
Patel added that the recent $166 million acquisition of Assertio, a US-based pharmaceutical company focused on specialty and oncology supportive care therapy, will allow the company to build a “highly differentiated, high-margin specialty oncology business in the US.”
